First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-... by Özgüroğlu, Mustafa, Prof, Kilickap, Saadettin, Prof, Sezer, Ahmet, Prof, Gümüş, Mahmut, Prof, Bondarenko, Igor, Prof, Gogishvili, Miranda, MD, Nechaeva, Marina, MD, Schenker, Michael, Prof, Cicin, Irfan, Prof, Ho, Gwo Fuang, Prof, Kulyaba, Yaroslav, MD, Zyuhal, Kasimova, MD, Scheusan, Roxana-Ioana, MD, Garassino, Marina Chiara, Prof, He, Xuanyao, PhD, Kaul, Manika, MD, Okoye, Emmanuel, MPH, Li, Yuntong, PhD, Li, Siyu, PhD, Pouliot, Jean-Francois, PhD, Seebach, Frank, MD, Lowy, Israel, MD, Gullo, Giuseppe, MD, Rietschel, Petra, MD

Get full text

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase... by Ascierto, Paolo A, Prof, Del Vecchio, Michele, MD, Mandalá, Mario, MD, Gogas, Helen, Prof, Arance, Ana M, MD, Dalle, Stephane, Prof, Cowey, C Lance, MD, Schenker, Michael, MD, Grob, Jean-Jacques, Prof, Chiarion-Sileni, Vanna, MD, Márquez-Rodas, Iván, Prof, Butler, Marcus O, MD, Maio, Michele, Prof, Middleton, Mark R, Prof, de la Cruz-Merino, Luis, MD, Arenberger, Petr, Prof, Atkinson, Victoria, MD, Hill, Andrew, FRACP, Fecher, Leslie A, MD, Millward, Michael, Prof, Khushalani, Nikhil I, Prof, Queirolo, Paola, MD, Lobo, Maurice, PharmD, de Pril, Veerle, MsC, Loffredo, John, PhD, Larkin, James, Prof, Weber, Jeffrey, MD

Get full text

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label,... by Paz-Ares, Luis, Prof, Ciuleanu, Tudor-Eliade, MD, Cobo, Manuel, MD, Schenker, Michael, MD, Zurawski, Bogdan, MD, Menezes, Juliana, MD, Richardet, Eduardo, MD, Bennouna, Jaafar, MD, Felip, Enriqueta, Prof, Juan-Vidal, Oscar, Prof, Alexandru, Aurelia, MD, Sakai, Hiroshi, MD, Lingua, Alejo, MD, Salman, Pamela, Prof, Souquet, Pierre-Jean, MD, De Marchi, Pedro, MD, Martin, Claudio, MD, Pérol, Maurice, MD, Scherpereel, Arnaud, Prof, Lu, Shun, Prof, John, Thomas, MD, Carbone, David P, Prof, Meadows-Shropshire, Stephanie, PhD, Agrawal, Shruti, PhD, Oukessou, Abderrahim, MD, Yan, Jinchun, MD, Reck, Martin, Prof

Get full text

Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival... by Petrylak, Daniel P, Prof, de Wit, Ronald, Prof, Chi, Kim N, Prof, Drakaki, Alexandra, MD, Sternberg, Cora N, Prof, Nishiyama, Hiroyuki, Prof, Castellano, Daniel, MD, Hussain, Syed A, Prof, Fléchon, Aude, MD, Bamias, Aristotelis, Prof, Yu, Evan Y, Prof, van der Heijden, Michiel S, PhD, Matsubara, Nobuaki, MD, Alekseev, Boris, Prof, Necchi, Andrea, MD, Géczi, Lajos, PhD, Ou, Yen-Chuan, Prof, Coskun, Hasan Senol, Prof, Su, Wen-Pin, Prof, Bedke, Jens, Prof, Gakis, Georgios, Prof, Percent, Ivor J, MD, Lee, Jae-Lyun, Prof, Tucci, Marcello, MD, Semenov, Andrey, PhD, Laestadius, Fredrik, MD, Peer, Avivit, MD, Tortora, Giampaolo, Prof, Safina, Sufia, MD, Garcia del Muro, Xavier, PhD, Rodriguez-Vida, Alejo, MD, Cicin, Irfan, Prof, Harputluoglu, Hakan, Prof, Tagawa, Scott T, MD, Vaishampayan, Ulka, Prof, Aragon-Ching, Jeanny B, MD, Hamid, Oday, PharmD, Liepa, Astra M, PharmD, Wijayawardana, Sameera, PhD, Russo, Francesca, MD, Walgren, Richard A, MD, Zimmermann, Annamaria H, MS, Hozak, Rebecca R, PhD, Bell-McGuinn, Katherine M, MD, Powles, Thomas, Prof

Get full text